An anti-HIV combination pill should be approved to prevent HIV infection in healthy people, an FDA advisory committee agreed overwhelmingly Thursday.
The combination of emtricitabine and tenofovir (Truvada) is safe and well tolerated, the committee decided, and helps prevent HIV infection when used daily by people at high risk.
The panel voted 19-3 that a risk-benefit analysis favored approval of the drug for men who have sex with men, and 19-2, with one abstention, for heterosexuals in couples in which one partner has HIV and the other does not.
Read the full story: http://hcp.lv/K2EONW
Source: MedPage Today
Community Outreach Is Enabling CeSHHAR to Close HIV Care Gaps in Zimbabwe
April 6th 2021The Centre for Sexual Health and HIV/AIDS Research Zimbabwe conducts evidence-based research related to HIV and AIDS, as well as provides and implements sexual and reproductive health education and interventions among sex workers, children, and adolescents, and in the area of masculinity.
Listen
Challenges, Adaption Needed in Conducting Research for Homeless Youth Living With HIV
April 8th 2024HIV testing, treatment, and intervention session delivery were among some areas that saw challenges in properly addressing youth experiencing homelessness during an HIV prevention trial.
Read More